RDD Pharma Announces Patents Granted In Israel And EU
Published: Feb 21, 2017
NEW YORK, Feb. 21, 2017 /PRNewswire/ -- RDD Pharma, a leader in developing treatments for anorectal disorders, announces the patent covering methods for treating fecal incontinence has been granted in Israel. The patent is based on the increase in resting anal pressure via a topical administration of RDD-0315, an alpha-agonist. Patents have already been granted in EU, China and Russia and are pending in U.S., Japan, Australia, Brazil, Canada, and India.
RDD Pharma has also received a notice of allowance in the EU for methods and devices for delivery of pharmaceutical agents related to the Capository, adding to granted patents in the U.S. and Israel. RDD-1219, using the Capository, is currently in Phase 3 development in Europe for the treatment of pain associated with chronic anal fissure.
About RDD Pharma
RDD is a privately held specialty pharma company, backed by Orbimed. RDD focuses on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders. The company has two clinical stage products which serve significant unmet needs: (1) RDD-1219 for chronic anal fissure, currently enrolling patients in a multicenter European Phase 3 study and (2) RDD-0315 for fecal incontinence, an indication for which there are no approved Rx products.
About RDD-0315 and Fecal Incontinence
RDD-0315 is being developed for the treatment of fecal incontinence, resulting from damaged or weakened anal sphincter muscles. A successful Phase 2a study in spinal cord injury patients has been completed in the EU and continued development is ongoing in the US. An estimated 20 million adults suffer from fecal incontinence in the U.S. With limited treatment options, RDD-0315 offers a promising Rx solution to address a large unmet need.
About RDD-1219 and Chronic Anal Fissure
RDD-1219 Capository has the potential to provide pain relief and to promote healing of the extremely painful and difficult to treat condition of chronic anal fissure. There are an estimated 235,000 new cases of anal fissure reported every year in the US, and about 40% of them persist for months and even years. M.H. Madalinski. World J Gastrointestinal Pharmacology Ther 2011 April 6; 2(2): 9-16.
Jennifer Filbey, Ph.D.
Business & Corporate Development
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rdd-pharma-announces-patents-granted-in-israel-and-eu-300410518.html
SOURCE RDD Pharma